18 results about "Complement inhibitor" patented technology

To provide further complement inhibitors with therapeutic potential in the treatment of many disorders.SOLUTION: Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.SELECTED DRAWING: None

The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The present invention relates to the medical device and ophthalmological industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural neuroprotective components. The invention describes an iontophoretic delivery of cannabinoid-based formulations designed for ophthalmic conditions, that comprise pharmaceutically acceptable charged vehicles, including but not limited to cationic surfactants, cyclodextrins, nanoparticles and microspheres, emulsions or liposomes, with control the size distribution, potential, osmolality and pH. In a further embodiment of the invention, the intraocular composition proposed further comprises one or more synergistic agents, including but not limited to neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers, antioxidants, saffron, and non-steroidal anti-inflammatory pharmaceutical drugs with pharmaceutically acceptable charged vehicle.

The present invention provides compounds and compositions for inhibiting complement-mediated damage to cells, tissues, or organs. [Solution] The present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. Furthermore, it provides methods for using cell-reactive compstatin analogs, for example, to inhibit complement-mediated damage to cells, tissues, or organs, for example, to treat complement-mediated disorders. Furthermore, it provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. Furthermore, it provides methods for using long-acting compstatin analogs, for example, to inhibit complement-mediated damage to cells, tissues, or organs, for example, to treat complement-mediated disorders. Furthermore, it provides targeted compstatin analogs and compositions comprising targeted compstatin analogs.

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

The present application relates to the preparation method and application of the polysaccharide of Herba Siegesbeckiae, which includes total polysaccharide SOP and two uniform polysaccharides SOPC2-3 and SOPC3. The experiments prove that the polysaccharide of Herba Siegesbeckiae has a significant inhibitory effect on complement activation, and can be further used as an active ingredient to prepare a new complement inhibitor. The cell model experiments prove that the polysaccharide of Herba Siegesbeckiae can significantly inhibit the inflammatory response of LPS-induced RAW264.7 cells, and has anti-inflammatory activity, and can be further used as an active ingredient to prepare an anti-inflammatory drug. The animal experiments prove that the polysaccharide of Herba Siegesbeckiae (SOP and SOPC3) can effectively relieve LPS-induced acute lung injury in mice, and can be further used as an active ingredient to prepare a drug for preventing and treating acute lung injury.

This application provides antibody-drug synergistic compounds, compositions, and methods for treating ocular diseases such as dry AMD, GA secondary to AMD, and exudative AMD. The antibody-drug synergistic compounds may include antibodies such as anti-angiogenic antibodies or anti-VEGF antibodies conjugated to small molecule complement inhibitors by a linker, or anti-complement antibodies conjugated to small molecule inhibitors of VEGF, VEGFR, PDGF, PDGFR, FGF, or FGFR by a linker. The linker conjugating the antibody and drug is hydrolyzable over time within the target eye, thereby allowing both the antibody and drug to exert their functions within the target eye. The compounds and compositions can confer superior efficacy compared to either the antibody or the drug alone due to the synergistic effect of the ADS compounds. Methods for treating age-related macular degeneration using ADS compounds and compositions are also provided.

The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy.

The present application provides antibody-drug synergistic compounds, compositions, and methods for treating ocular diseases, such as dry AMD, GA secondary to AMD, and exudative AMD. The antibody-drug synergistic compound may comprise an antibody such as an anti-angiogenic antibody or an anti-VEGF antibody linked to a small molecule complement inhibitor through a linking group; or an anti-complement antibody linked to a small molecule inhibitor of VEGF, VEGFR, PDGF, PDGFR, FGF or FGFR via a linking group. A linking group linking the antibody and the drug may hydrolyze in the eye of the subject over time such that both the antibody and the drug function in the eye of the subject. Due to the synergy of the ADS compounds, the compounds and compositions can confer better efficacy than the antibody or drug alone. Methods of treating age-related macular degeneration using the ADS compounds and compositions are also provided.

The invention relates to a herba siegesbeckiae polysaccharide as well as a preparation method and application thereof. The herba siegesbeckiae polysaccharide comprises a herba siegesbeckiae total polysaccharide SOP and two homogeneous polysaccharides SOPC2-3 and SOPC3. Experiments prove that the herba siegesbeckiae polysaccharide has a remarkable inhibition effect on complement activation and can be further used as an active ingredient for preparing a novel complement inhibitor; a cell model experiment proves that the herba siegesbeckiae polysaccharide can remarkably inhibit inflammatory response of RAW264.7 cells induced by LPS, has anti-inflammatory activity and can be further used as an active component for preparing anti-inflammatory drugs; animal experiments prove that the herba siegesbeckiae polysaccharide (SOP and SOPC3) can effectively relieve LPS-induced acute lung injury of mice, and can be further used as an active component to prepare the medicine for preventing and treating the acute lung injury.

The present disclosure relates, inter alia, to compositions comprising a human complement inhibitor and use of the compositions in methods of treating or preventing complement-related disorders. In some embodiments, the inhibitor is administered chronically to patients. In some embodiments, the inhibitor is administered to a patient in an amount and frequency such that systemic complement inhibition is maintained and escape is prevented. In some embodiments, the composition comprises an antibody, or antigen-binding fragment thereof, which binds to the protein constituting the C5 component of human complement or to a fragment of the protein, such as C5a or C5b.

The present disclosure relates to the use of a Factor B inhibitor in the treatment of paroxysmal nocturnal hemoglobinuria. Specifically, the present disclosure relates to the use of the Factor B inhibitor or a pharmaceutically acceptable salt thereof in the preparation of a formulation for treating paroxysmal nocturnal hemoglobinuria (PNH) previously using a C5 complement inhibitor, wherein the Factor B inhibitor is represented by formula (I), (II) or (III).

To provide an inhibitor of complement system.SOLUTION: Compounds of Formula (I), and pharmaceutically acceptable salts thereof, are disclosed. Also provided are pharmaceutical compositions comprising such compounds, and methods of using the compounds and compositions in the treatment or prevention of diseases or conditions characterized by aberrant complement system activity.SELECTED DRAWING: None

The invention discloses a complement inhibitor as well as a preparation method and application thereof, and particularly discloses a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof. The compound shown in the formula (I) has better in-vitro complement pathway hemolysis inhibition activity or better in-vivo half-life period, and lays a foundation for developing medicines for treating complement-related diseases. And R1-R2-R3-R4 (I) (In the formula, R1, R2, R3 and

The use of urine C5b-9 (uC5b-9) as a highly accurate and superior biomarker that is well correlated to complement activity in local tissue affected by complement-mediated diseases (e.g., diseases with renal lesion components) is provided. The biomarkers may be used, for example, in the absence of systemic complement inhibition, to treat and / or monitor diseases mediated by such complements using complement inhibitors targeted to local tissue affected by such complements.